Previous 10 | Next 10 |
2024-06-07 15:00:58 ET More on the markets Going Into June, SPY Or VXF, Which Is The Better Buy? (Technical Analysis) SPY: 2 Options To Balance Out A Highly Concentrated Index Bitcoin's Fading Action Is A Huge Warning For Stock Market Liquidity Citi – ...
2024-06-06 12:38:52 ET Summary FibroGen, Inc. top-line data from the phase 2/3 PanCAN Precision Promise study, using pamrevlumab for the treatment of patients with metastatic pancreatic cancer, expected mid-2024. Topline data from the phase 3 LAPIS study, using pamrevlumab for the...
2024-06-06 10:47:18 ET More on 2seventy bio 2seventy bio, Inc. (TSVT) Q1 2024 Earnings Call Transcript 2seventy Bio: Maximizing ABECMA's Potential To Fuel A Turnaround Bristol-Myers posts Q1 beat despite growth headwinds Bristol Myers, 2seventy bio's Abecma a...
- Phase 2b Data Presented at EASL and Published in NEJM Show Potential for Bulevirtide 10 mg in Combination with Pegylated Interferon Alfa-2a as Finite Therapy for People with Chronic Hepatitis Delta - - Data Published in NEJM Demonstrate 46% of Patients Taking Bulevirtide 10 mg with ...
2024-06-05 14:05:27 ET Gilead Sciences, Inc. (GILD) Jefferies 2024 Global Healthcare Conference June 5, 2024 11:00 AM ET Company Participants Merdad Parsey - Chief Medical Officer Conference Call Participants Michael Yee - Jefferies Presentation ...
NORTHAMPTON, MA / ACCESSWIRE / June 5, 2024 / Emma was a 28-year-old nursing student when she was diagnosed with triple-negative breast cancer. She had always wanted children and, once she learned that her treatment could affect her fertility, she found herself needing to make a quick family pla...
- Positive Results from Two-year Interim Analysis Includes Participants from Phase 3 RESPONSE Study and are Highly Consistent with One-year Interim Analysis - - Reduction in Patient-Reported Pruritus (Itching) was Rapid and Durable in Participants with Moderate to Severe Symptoms - ...
2024-06-03 14:01:03 ET More on Gilead Sciences, Arcus Biosciences Gilead Sciences: Seriously Undervalued At Peak Pessimism Gilead Sciences: Disappointing Fundamentals And Sentiment, But Still Bullish Arcus Biosciences: A Preview Of Their Outlook Ahead Of ASCO ...
-- After More Than Four Years of Follow-up in the Pivotal ZUMA-3 Study, Median Overall Survival (OS) was 26 Months and the OS Rate was 40% at 48 Months -- -- Survival Benefit was Seen Regardless of Age, Prior Treatment or Subsequent Allogeneic Stem Cell Transplant Status -- ...
-- At Median Follow-Up of 24.2 Months, No Additional Risks of Adverse Events Related to Yescarta Were Observed -- -- Findings Also Suggest Efficacy Trend with Median Progression-Free Survival and Durability of Response of More Than a Year -- -- Data Presented Orally at the...
News, Short Squeeze, Breakout and More Instantly...
NORTHAMPTON, MA / ACCESSWIRE / July 1, 2024 / Jim Candler had a successful 40-year career in system operations before coming to Gilead three years ago to bring his tech expertise to the Human Resources team. "I was hired at 71 years old. What does that say about Gilead?" says Jim, Senior Direct...
2024-07-01 06:50:00 ET Most retirees prefer low turnover in their investment portfolios. The less drama, the better. That way, they can focus on doing what they enjoy instead of worrying about their investments. Three Motley Fool contributors think they've found magnificent stocks retir...
2024-06-24 13:00:04 ET Michael Yee from Jefferies issued a price target of $85.00 for GILD on 2024-06-24 10:57:00. The adjusted price target was set to $85.00. At the time of the announcement, GILD was trading at $71.24. The overall price target consensus is at $80.71 wi...